Oxurion N.V. (TBGNF) Stock Analysis
DELISTED
What happened to Oxurion N.V. (TBGNF) stock?
Oxurion N.V. (TBGNF) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
P/E 1.68 means the share price is 1.68 times one year of earnings per share. Market cap $434M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Oxurion N.V. (TBGNF). Oxurion NV is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases. Their lead product, JETREA, addresses vitreomacular adhesion/traction, while they also advance novel therapies for diabetic macular edema.
Last analyzed: Mar 18, 2026Oxurion N.V. (TBGNF) Healthcare & Pipeline Overview
TBGNF OTC Market Information
TBGNF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy TBGNF shares?
No. TBGNF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for TBGNF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TBGNF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Oxurion N.V.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.